Screening newborns for TP53.

摘要

In the September issue of The Lancet Oncology, Achatz and colleagues discuss the possibility of screening newborns in southeast Brazil for a highly prevalent TP53 mutation (1:300 individuals) that predisposes to many cancers. The authors present the justifications and the problems associated with such a screening effort, and conclude that "on the basis of current scientific and medical knowledge the R337H mutation does not meet all the criteria for mass newborn screening".